Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bio-Techne (NASDAQ: TECH) has partnered with Lunaphore to create an automated spatial multiomics workflow aimed at enhancing research in disease analysis and therapeutic development. This collaboration integrates Bio-Techne's RNAscope™ technology with Lunaphore's seqIF™ system for simultaneous detection of protein and RNA biomarkers. The innovative solution promises flexibility in panel designs and is expected to streamline workflows for researchers focused on various diseases, including cancer and neurodegenerative disorders. With RNAscope™'s extensive catalog of over 45,000 probes and proven sensitivity, the partnership aims to significantly accelerate the discovery of novel diagnostics and therapeutics.
Bio-Techne Corporation (NASDAQ: TECH) announced its participation in the American Association for Cancer Research (AACR) annual meeting from April 14-19, 2023, in Orlando, Florida. The company will showcase its extensive portfolio of products aimed at advancing cancer research and facilitating cell and gene therapy development. Featured products include reagents, immunoassays, proteomic instruments, and spatial biology solutions. Several scientists from Bio-Techne will present posters on topics such as biomarkers, structural biology, and spatial biology. Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and employs about 3,000 people globally.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on May 3, 2023, at 8:00 a.m. CDT to discuss its third quarter 2023 financial results. Investors can dial in at 1-877-300-8521 for U.S. calls or 1-412-317-6026 for international calls, using Conference ID 10177426. A rebroadcast will be available for those unable to join live, from 11:00 a.m. CDT on May 3 to 11:00 p.m. CDT on June 3, 2023. Bio-Techne is a leader in developing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales for fiscal 2022 and employing around 3,000 employees globally.